

May 9, 2024

BSE Limited Code: 532321

P J Towers, Dalal Street, <u>Mumbai-400001</u>

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated May 9, 2024 titled "Zydus receives final approval from USFDA for Dapsone Gel, 7.5%".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Code: Zyduslife



Zydus receives final approval from USFDA for Dapsone Gel, 7.5%

Ahmedabad, India, 09 May, 2024

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to market Dapsone Gel, 7.5%, (USRLD: Aczone® Gel 7.5%).

Dapsone Gel is used to treat acne and will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India).

Dapsone Gel, 7.5% had annual sales of USD 35.8 mn in the United States (IQVIA MAT March 24).

The group now has 395 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.

(**as of 31*^{*st*} *December 2023*)



For further information please contact : The Corporate Communications Department

Zydus Lifesciences Limited

(formerly known as Cadila Healthcare Limited)

Regd. Office: 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone: +91-79-71800000, +91-79-48040000 | website: www.zyduslife.com

CIN: L24230GJ1995PLC025878